Aldose reductase inhibitors and methods of use thereof
View Patent ↗The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.
1. A compound of Formula (I)
wherein,
R 1 is CO 2 R 2 ;
R 2 is H, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-hydroxyalkyl, or (C 1 -C 6 )-aminoalkyl;
X 1 is H or halogen;
X 2 is H or halogen;
Y is a bond, C═O, C═S, C═NH, or C═N(C 1 -C 4 )-alkyl;
Z is
A 1 is NR 7 , O, S or CH 2 ;
A 2 is N or CH;
A 3 is NR 7 , O, or S;
R 3 through R 6 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio, (C 1 -C 4 )-alkylsulfinyl, or (C 1 -C 4 )-alkyl sulfonyl; and
R 7 is hydrogen, C 1 -C 4 alkyl, or C(O)O—(C 1 -C 4 )-alkyl;
or a pharmaceutically acceptable salt or solvate thereof.
2. The compound of claim 1 , wherein
R 2 is hydrogen or (C 1 -C 6 )-alkyl;
Y is C═O;
A 1 is NR 7 , O, or S;
A 2 is N;
A 3 is O, or S; and
R 3 through R 6 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio, (C 1 -C 4 )-alkylsulfinyl, or (C 1 -C 4 )-alkylsulfonyl;
or a pharmaceutically acceptable salt or solvate thereof.
3. The compound of claim 1 , wherein Z is
or a pharmaceutically acceptable salt or solvate thereof.
4. The compound of claim 3 , wherein
R 2 is hydrogen or (C 1 -C 6 )-alkyl;
Y is C═O;
A 1 is NR 7 , O, or S;
A 2 is N;
R 3 through R 6 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio, (C 1 -C 4 )-alkylsulfinyl, or (C 1 -C 4 )-alkylsulfonyl; and
R 7 is hydrogen, C 1 -C 4 alkyl, or C(O)O—(C 1 -C 4 )-alkyl; or a pharmaceutically acceptable salt or solvate thereof.
5. The compound of claim 3 , wherein
R 2 is hydrogen or (C 1 -C 6 )-alkyl;
X 1 is H;
X 2 is H;
Y is C═O;
A 1 is S;
A 2 is N; and
R 3 through R 6 are independently hydrogen, halogen, or haloalkyl, or a pharmaceutically acceptable salt or solvate thereof.
6. The compound of claim 1 , wherein Z is
or a pharmaceutically acceptable salt or solvate thereof.
7. The compound of claim 6 , wherein
R 2 is hydrogen or (C 1 -C 6 )-alkyl;
Y is C═O;
R 3 through R 6 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio, (C 1 -C 4 )-alkylsulfinyl, or (C 1 -C 4 )-alkylsulfonyl; and
R 7 is hydrogen, C 1 -C 4 alkyl, or C(O)O—(C 1 -C 4 )-alkyl; or a pharmaceutically acceptable salt or solvate thereof.
8. The compound of claim 1 , wherein
R 2 is hydrogen;
X 1 is Cl;
X 2 is Cl;
Y is C═O;
R 3 through R 6 are independently hydrogen, halogen, or haloalkyl; and
R 7 is hydrogen, (C 1 -C 4 )-alkyl, or C(O)O-tert-butyl; or a pharmaceutically acceptable salt or solvate thereof.
9. The compound of claim 1 , wherein
R 2 is hydrogen;
X 1 is Cl;
X 2 is Cl;
Y is C═O;
A 3 is is NR 7 , O or S; and
R 3 , R 5 , and R 6 are hydrogen;
R 4 is hydrogen or halogen; and
R 7 is hydrogen, (C 1 -C 4 )-alkyl, or C(O)O-tert-butyl; or a pharmaceutically acceptable salt or solvate thereof.
10. The compound of claim 1 , selected from the group consisting of:
or a pharmaceutically acceptable salt or hydrate of any one of the foregoing.
11. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt and the counter ion is selected from the group consisting of: sodium, lithium, potassium, calcium, magnesium, zinc, ammonium, and tetrafluoroborate.
12. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt and the counter ion is selected from the group consisting of:
13. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
14. A method of inhibiting aldose reductase activity in a subject comprising administering a therapeutically effective amount of the compound of claim 1 to a subject in need thereof.
15. The method of claim 14 , wherein the subject is diabetic.
16. The method of claim 14 , wherein the subject is a human.
17. A method of treating a disorder in a subject comprising administration of a therapeutically effective amount of the compound of claim 1 to a subject in need thereof, wherein the disorder is selected from the group consisting of atherosclerosis, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, cardiovascular disease, peripheral vascular disease, angiogenesis disorder, tissue damage and diabetic cardiomyopathy.
18. The method of claim 17 , wherein the disorder is atherosclerosis, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, or diabetic cardiomyopathy.
19. A method to treat a skin disorder or promote healthy aging of skin, comprising applying a therapeutically effective amount of the compound of claim 1 to the skin of a human subject in need thereof.
20. A method of treating a subject with evolving myocardial infarction comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1 .